Concord Healthcare Group Co., Ltd. Class H (HK:2453)
:2453
Top Page
Concord Healthcare Group Co., Ltd. Class H
(2453)
Select Model
Select Model
Rating:38Underperform
Price Target:
HK$1.50
▼(-18.03% Downside)
Action:ReiteratedDate:11/22/25
Concord Healthcare Group Co., Ltd. is currently facing significant financial and technical challenges. The most impactful factor is the company's poor financial performance, characterized by declining revenues, persistent losses, and high leverage. Technical analysis further supports a bearish outlook with oversold conditions and a strong downward trend. Valuation metrics are also unfavorable, with a negative P/E ratio and no dividend yield. These factors collectively result in a low overall stock score.
Positive Factors
R&D focus
A sustained corporate emphasis on R&D supports pipeline development and product differentiation in pharmaceuticals. Over 2-6 months this underpins future revenue opportunities, patentable assets and strengthens competitive positioning versus peers reliant on generics.
Negative Factors
Declining revenue and persistent losses
Ongoing top-line contraction and continued losses indicate structural demand or execution issues, reducing reinvestment capacity and eroding margins. Persisting decline constrains growth and increases reliance on capital markets or asset sales to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
R&D focus
A sustained corporate emphasis on R&D supports pipeline development and product differentiation in pharmaceuticals. Over 2-6 months this underpins future revenue opportunities, patentable assets and strengthens competitive positioning versus peers reliant on generics.
Read all positive factors
Concord Healthcare Group Co., Ltd. Class H (2453) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$971.74M
Dividend YieldN/A
Average Volume (3M)590.21K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth-21.84%
EPS Growth-20.73%
CountryHK
Employees567
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.11
Shares Outstanding313,874,630
10 Day Avg. Volume440,520
30 Day Avg. Volume590,206
Financial Highlights & Ratios
PEG Ratio-1.56
Price to Book (P/B)4.49
Price to Sales (P/S)19.04
P/FCF Ratio-14.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Concord Healthcare Group Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Concord Healthcare Group Co., Ltd. provides oncology healthcare service for cancer patients and medical institutions in China. It also offers oncology-related services, including sales and installing of medical equipment and software; management a...
How the Company Makes Money
Concord Healthcare Group generates revenue primarily through the sales of its pharmaceutical products, which include both prescription and over-the-counter medications. The company has established strategic partnerships with various healthcare ins...
Concord Healthcare Group Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
10
Very Negative
Balance Sheet
20
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 370.22M | 388.31M | 538.65M | 472.17M | 470.50M | 166.32M |
| Gross Profit | -32.36M | -67.25M | -65.09M | -197.46M | -92.76M | -17.27M |
| EBITDA | -153.23M | -194.46M | -172.58M | -355.51M | -356.26M | -229.19M |
| Net Income | -437.94M | -443.22M | -373.09M | -541.40M | -816.59M | -583.26M |
Balance Sheet | ||||||
| Total Assets | 5.77B | 5.91B | 5.24B | 6.08B | 6.66B | 5.90B |
| Cash, Cash Equivalents and Short-Term Investments | 170.03M | 337.12M | 49.23M | 136.06M | 136.09M | 424.83M |
| Total Debt | 3.23B | 3.21B | 2.64B | 2.85B | 2.48B | 2.21B |
| Total Liabilities | 3.95B | 4.01B | 3.37B | 3.84B | 8.08B | 6.52B |
| Stockholders Equity | 1.54B | 1.65B | 1.60B | 1.69B | -1.56B | -678.14M |
Cash Flow | ||||||
| Free Cash Flow | 100.47M | -500.12M | 18.11M | -175.66M | -584.24M | -915.43M |
| Operating Cash Flow | -67.57M | -185.96M | 201.85M | -93.64M | 45.87M | -51.85M |
| Investing Cash Flow | -229.03M | -668.09M | -182.34M | -100.33M | -945.04M | -851.51M |
| Financing Cash Flow | 355.09M | 1.02B | -105.43M | 184.37M | 505.06M | 1.17B |
Concord Healthcare Group Co., Ltd. Class H Technical Analysis
Negative
1.83
Price Trends
1.41
Negative
1.65
Negative
3.14
Negative
Market Momentum
-0.06
Negative
44.45
Neutral
63.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2453, the sentiment is Negative. The current price of 1.83 is above the 20-day moving average (MA) of 1.28, above the 50-day MA of 1.41, and below the 200-day MA of 3.14, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.45 is Neutral, neither overbought nor oversold. The STOCH value of 63.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2453.
Concord Healthcare Group Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | HK$7.62B | 43.03 | 0.62% | ― | -13.92% | -36.32% | |
60 Neutral | HK$1.03B | 39.67 | 1.27% | ― | -4.30% | 13.83% | |
56 Neutral | HK$483.68M | -10.63 | 27.04% | ― | 2.30% | ― | |
52 Neutral | HK$1.68B | 117.78 | 0.48% | 0.49% | -0.55% | 45.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.59B | 20.66 | 5.64% | 1.20% | 2.05% | -285.88% | |
38 Underperform | HK$971.74M | -4.57 | -15.15% | ― | -21.84% | -20.73% |
* Healthcare Sector Average
HK:2453
Concord Healthcare Group Co., Ltd. Class H
1.40
-5.46
-79.59%
HK:3309
C-MER Eye Care Holdings Limited
1.27
-0.15
-10.56%
HK:3869
Hospital Corporation of China Ltd
3.50
-3.30
-48.53%
HK:3886
Town Health International Medical Group Ltd.
0.25
>-0.01
-2.37%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
12.12
-2.16
-15.13%
HK:6639
Arrail Group Ltd.
1.83
-0.20
-9.90%
Concord Healthcare Group Co., Ltd. Class H Corporate Events
Concord Healthcare Names AI Business Head Jiang Wei as New President
Jan 12, 2026
Concord Healthcare Group has announced a leadership reshuffle, with president Fu Xiao stepping down from the role effective 12 January 2026 as part of normal succession planning, while remaining an executive director and becoming an adviser to the...
Concord Healthcare Marks First Full Year of Guangzhou Proton Therapy Center Operations
Dec 30, 2025
Concord Healthcare Group Co., Ltd. announced that the proton therapy center at its subsidiary Guangzhou Concord Cancer Center has been in official operation for one year as of 16 December 2024, with all four treatment rooms now in use and key oper...
Concord Healthcare Gains Approval for Advanced Oncology Drug Use in Greater Bay Area
Dec 8, 2025
Concord Healthcare Group Co., Ltd. announced that its subsidiary, Guangzhou Concord Cancer Center, has been approved to be included in the list of designated medical institutions under the Measure of Using Hong Kong Registered Drugs and Medical De...
Concord Healthcare Streamlines Governance with Supervisory Committee Abolition
Dec 5, 2025
Concord Healthcare Group Co., Ltd. announced the results of its 2025 Extraordinary General Meeting (EGM), where a special resolution was passed to abolish the Supervisory Committee. The audit committee of the Board will now assume the responsibili...
Concord Healthcare Group Announces EGM to Revise Governance Structure
Nov 17, 2025
Concord Healthcare Group Co., Ltd. has announced an extraordinary general meeting (EGM) scheduled for December 5, 2025, to discuss the abolition of the Supervisory Committee and propose amendments to the Articles of Association and procedural rule...
Concord Healthcare’s Share Pledge Strategy with China Credit
Nov 4, 2025
Concord Healthcare Group Co., Ltd. announced that its controlling shareholder, Beijing Concord, has pledged an additional 35,602,300 H shares to China Credit as security for a loan facility. This move is part of an ongoing strategy to secure oblig...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.